We expectedly observed that both CD41+ platelets and CD45+ WBCs within whole SCD blood treated with crizanlizumab occlude microfluidic channels less than untreated SCD blood samples (Fig. 6c) at a lowered percentage rate similar to completed clinical trials (Supplementary Fig. 11)70. This evidence concerns the gene ITGA2B and Schnyder corneal dystrophy.